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Some 200 scientists and clinicians gathered at Keble
College in Oxford, UK from 30th July to 2nd August for this
biennial meeting, which has grown immensely both in size
and quality of research presentations. The college, built in
the holy zebra style (1870), and the adjacent famous uni-
versity natural history museum formed a most charming
environment for the meeting. The conference was orga-
nized and co-chaired by Carol M Black (Royal Free Hospi-
tal, London, UK) and Joseph H Korn (Boston University
School of Medicine, Boston, MA, USA). Plans are to
arrange the next meeting in the Boston area in the summer
of 2002.
Hunting for pathological genes in
scleroderma
Fiona Brew (Cambridge, UK) presented the Affymetrix
Gene Chip technology, which is a powerful method allow-
ing analysis of a large number of gene expressions from
single cells. It was presented as versatile, having high sen-
sitivity and low risk for false-positive results. It is best
suited for classification of single-cell diseases such as
leukemias or other malignancies, and has found clinical
application in distinguishing between acute lymphoblastic
and myeloid leukaemia. The price is high, however, and as
Constantin Bona pointed out in the discussion there are
several causes for negative results. To this Dr Brew
responded that one needed only 3–5 gene copies
expressed per cell.
Next, David Strehlow (Boston, MA, USA) presented excit-
ing data regarding a new genetic marker relating to sclero-
derma. This work utilized in parts the cDNA microarray
technique above. As demonstrated by in situ hybridisation,
the gene encoding the protease nexin 1 (PN1) is
expressed only in scleroderma skin. Comparing cultured
fibroblasts from normal, lesional, and nonlesional sclero-
derma skin, it was found that mRNA as well as protein
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secretion was 3–5 times higher in scleroderma. A search
for other overexpressed genes by the microarray chip
technique revealed overexpression of heat shock protein
90 (HSP90), a chaperon found in complex with other
HSPs. HSP90 is essential for steroid hormone signalling.
Expression was higher in lesional than in nonlesional skin.
In cultured fibroblasts collagen transcription was doubled
3h after exposure to HSP90. The effect lasted up to 24h.
Geldanomycin is known to inhibit HSP90, and it was
shown that geldanomycin inhibited both collagen synthe-
sis and the known effect of transforming growth factor b,
TGF-b, on collagen synthesis. This prompted investigation
of the mechanism for this inhibition. Geldanomycin was
shown to inhibit the movement of SMADs from the cyto-
plasm to the nucleus. SMADs are proteins that are essen-
tial for the transmission of extracellular signals from TGF-b
superfamily peptides via cell surface receptors to the
nucleus. Furthermore it could be shown that HSP90 binds
to SMAD3 but not to SMAD4. The biologic implication of
SMAD3 binding may be that its attachment to the cell
surface TGF-b receptors is broken. SMAD3 can then bind
to SMAD4, and the complex can be transported to the
nucleus and there influence promoter regions of certain
genes. In essence the work suggests a new disturbed sig-
nalling pathway in scleroderma with profound effects on
nuclear gene regulation of components of the extracellular
matrix, such as collagen. In the extension this could lead to
new therapeutic approaches. The designation of SMAD
proteins comes from homologies with a Drosophila
protein family called MAD and the C. elegans homologue
SMA. The interested reader is referred to two recent
reviews on the subject [1,2].
Timothy Wright (Pittsburgh, PA, USA) presented his
work on gene expression in lesional and nonlesional skin
cultured fibroblasts. The approach was to utilize a tech-
nique called serial analysis of gene expression, SAGE,
allowing simultaneous display of 9–13 base-pair tags.
The results were still incomplete, but indicated several
differences between unaffected and affected skin fibrob-
lasts. It was, however, pointed out in the discussion that
even unaffected scleroderma skin is not normal. The
technique used, although very powerful, did not pick up
HSP90 overexpression.
Lance Fors (Madison, WI, USA) presented another analytic
technique called Cleavase Fragment Length Polymorphism
(CFLP), which is the flagship of the company at which he is
chief executive officer. It is based on conformation rather
than sequence specific Cleavase® enzymes, which are
thermostable and structure-specific. They recognize and
cleave the junctions between single-stranded and double-
stranded DNA at the 5¢ side. The newly formed fragments
fold in a characteristic way and their analysis gives informa-
tion on single nucleotide polymorphisms, SNP. SNPs are
the most common genetic variations among individuals,
occurring at an estimated frequency of at least 1% in the
population and affecting approximately 1 in 1000
nucleotides or as many as a million bases per genome.
CFLP has the advantage over PCR in being faster and
easier to use, since it does not involve gel electrophore-
sis and eliminates the risk of carry-over contaminants. It
has been successfully applied to routine detection of
coagulation factor V mutation (Leiden), which predis-
poses to thrombosis. This technique promises to come
into wide use for detection of genetic diseases and gene
expression. What it will bring for scleroderma research
remains to be seen.
Animal models and the pathogenesis of
scleroderma
Sergio Jimenez (Philadelpia, PA, USA) reviewed the field
of experimentally induced and spontaneous animal models
of fibrosis, concentrating on the spontaneous tight skin
mouse (TSK1) model. This model was first found in 1976,
and is linked to a duplication of parts of the fibrillin 1 gene,
which leads to overproduction of collagen in the skin,
heart and other internal organs. In its homozygous form it
is lethal. A similar abnormality has been described in
humans by Stephanie Jablonska of Warsaw, Poland and
called congenital facial dystrophy. Dr Jimenez, who
worked for years elucidating the TSK abnormality, has (in
my mind) unjustly been accused of studying an irrelevant
model. The gene duplication is 40kb long, which is rather
unusual. It has two TGF-b-binding sites and one extra
RGD-binding site. This explains how the increased colla-
gen production comes about. New experiments have
shown that the TSK1 model is not dependent on T cell
function, which is one limitation of this model.
Jose Pablos (Madrid, Spain) had studied the TSK skin in
the neonatal period from the first to the 35th week. Both
normal and TSK mice had more proliferation and apopto-
sis only in the newborn state and not later. Thus neither
defect (apoptosis and increased proliferation) was
involved in the TSK abnormality, which is characterized by
a continued high rate of collagen and matrix synthesis in
neonates rather than by acquisition of new genes, accord-
ing to Pablos.
Constantin Bona (New York, NY, USA), who had shown
previously that the defective fibrillin-1 gene in TSK mice
had indeed a higher binding capacity for TGF-b, had now
studied TSK offspring with interleukin (IL)-4R or TGF-b
mutated genes. IL-4R–/– animals showed a normal pheno-
type, whereas heterozygous animals were not protected.
TGF-b–/– was lethal and heterozygous animals had the
TSK phenotype. No mutation affected lung fibrosis, which
thus may have a different pathogenesis. He also indicated
that mice transgenic with the mutant fibrillin gene demon-
strate thicker skin but no lung disease, raising questions
about tissue-specific expression of the transgene.Arthritis Research    Vol 3 No 1 Wollheim et al
Stephen Clark (Farmington, CT, USA) reported studies on
collagen gene expression in TSK mice. Only a subset of
fibroblasts is activated, and remains activated, in culture.
Collagen 1a1 was almost three times more highly
expressed in these cells and TGF-b receptor 1 (TGF-bR1)
was also upregulated, but to a lesser degree. Taken
together all the information supports the hypothesis that
fibrillin–TGF-b interactions are important for persisting
fibroblast activation in vivo. It remains to be shown how rel-
evant this is for understanding scleroderma in humans.
Several transgenic approaches are in progress, some
using the elegant gene switch technique involving Cre lox
guided gene expression, which is a refinement of the
knockout technique and allows the turning off of selected
genes in certain tissues at precise time points only.
Christopher Denton (London, UK) reported progress in
studies of mice transgenic for TSK. He has identified
enhancer elements in the far upstream region of the
col1a2 gene in TSK mice. These elements were expressed
in transgenic animals and correlated to fibrosis. Interest-
ingly, the altered gene seems specific for fibroblasts, and
does not affect collagen synthesis by osteoblasts.
Humphrey Gardener (La Jolla, CA, USA), working with
integrins, had previously shown that fibroblasts from inte-
grin a1 null mice lack feedback inhibition of collagen pro-
duction when grown in collagen gels. He now presented
new data indicating that a1 integrins prolong collagen
promoter activity. Interestingly, mice with a1b1 integrin
mutation had normal skin, despite increased hydroxypro-
line incorporation, indicating increased collagen synthesis.
However this could be explained by a concomitant
increased expression of some collagenases. If mice with
the a1 deletion are crossed with collagenase resistant
mice, a thick skin phenotype is expressed.
The a1b1 integrin was originally called very late antigen-1,
VLA-1, on the basis of its expression on activated T lym-
phocytes. Philip Gotwals (Cambridge, MA, USA) pointed
out the upregulation of this integrin in certain models of
inflammation, such as Mycobacterium butirricum mineral
oil arthritis. A monoclonal antibody to VLA-1/a1b1 integrin
inhibits edema and inflammation in these animals. VLA-1 is
only expressed on tissue cells. It may be involved in some
forms of renal disease, and is a perhaps a putative target
for intervention in scleroderma.
TGFb b biology and signalling
Anita Roberts (Bethesda, MA, USA) was the keynote
speaker in this session. She pointed out that of the three
forms of TGFb, TGFb1 is most important. The TGFs acti-
vate specific cell-surface receptors and these, upon activa-
tion, act as serine-threonine kinases. This starts the
above-mentioned SMAD pathway that eventually leads to
nuclear gene activation. There are at least nine different
SMADs; some are activators, one is only a transporter
(SMAD4), and two (SMADs 6 and 7) are inhibitors.
SMAD7 is activated by IFNg. To study the biology further,
gene disruption experiments had been performed, which
showed that all total deletions were lethal with the excep-
tion of SMAD3. SMAD3–/– animals show progressive
wasting and mucosal infections as well as abscesses.
TGFb injection into wild-type animals causes mobilization
of inflammatory cells, but this does not happen in the
SMAD3–/– animals. Lack of chemotaxis and accelerated
early phases of wound healing was another feature of the
mutated animals. Furthermore, re-epithelialization was
delayed both in homozygous and heterozygous animals, as
was the normal auto-induction of TGFb. The role of TGFb
in bleomycin-induced fibrosis and in early phases of radia-
tion fibrosis was also emphasized. Interestingly, SMAD3–/–
mice were resistant to radiation.
John Varga (Chicago, IL, USA) further explored SMAD
biology in an effort to understand their regulatory functions
in cell biology. He took the difficult approach by studying
regulation in normal rather than in transformed cells.
Normal adult skin fibroblasts as well as foreskin fibroblasts
express both SMAD3 and SMAD4 after stimulation with
TGFb, and transport of these mediators to the nucleus
takes place. A surprising finding was that mRNA for
SMAD3 diminished after TGFb administration. TGFb also
enhances SMAD7, which is an inhibiting SMAD. This indi-
cates an autoregulation of SMAD activity and may explain
some conflicting results regarding the influence of TGFb
on collagen synthesis in vivo. It is known that IFNg abro-
gates TGFb signaling. This effect is SMAD-mediated.
Thus TGFb not only triggers SMAD activation when ligat-
ing its cell membrane receptor, but also has a profound
effect on SMAD expression and intracellular trafficking. A
short general review on the regulation of SMAD activity
was published by Wrana [1].
Sara Dallas (Manchester, UK) presented her work on
latent TGFb and its binding protein, latent TGFb-binding
protein or LTBP1. TGFb proteins are secreted in a latent
form of approximately 100kDa, which binds to LTBP1
with a size of about 190kDa. LTBP1 belongs to the fibrillin
superfamily and is also a structural extracellular matrix
protein that binds calcium. LTBP1 has mostly been
studied in relation to bone and cartilage, but its relation to
fibrillin and binding of TGFb makes it a possible target for
intervention in scleroderma.
The final speaker in this session, Ante Jelaska (Boston MA,
USA), dealt with TGFb and apoptosis. TGFb induces a cell
called a myofibroblast, expressing both the muscle cell
marker alpha smooth muscle antigen and collagen. These
cells are removed by apoptosis. Examining normal and scle-
roderma skin, it was found that 30% of normal fibroblasts
were “apoptosis resistant”, whereas only 5% of lesional
fibroblasts in culture showed this resistance. Sclerodermafibroblasts thus are more prone to apoptosis. TGFb
reduces apoptosis.
TGFb b as a target for therapy
Stephen Ledbetter (Framingham, MA, USA) stated three
principle methods for inhibition: antibodies, soluble recep-
tors and low molecular weight compounds. He focused on
a monoclonal antibody named 1D11. This is a high-affinity
antibody which neutralizes all three TGFb forms, 1, 2 and
3, and has a half-life of 15h in the rat. In a genetic rat
model of hypertension and renal fibrosis, 1D11 reduced
elevated levels of TGFb1 and TGFb2, reduced proteinuria,
and reduced expression of the alpha smooth muscle
antigen and collagen synthesis in fibroblast cultures taken
from renal biopsies. 1D11 also reduced blood pressure
and increased renal medullar blood flow. However, disap-
pointingly, it did not increase glomerular filtration rate in
these animals. Another model under study was the unilat-
eral renal artery obstruction, also in rats. These have in
increased production of collagen type III mRNA and
increased apoptosis. 1D11 normalized both abnormalities.
The third model was subtotal (5/6) nephrectomy. 1D11
improved survival as do angiotension-converting enzyme
inhibitors in this model. The antibody also inhibits collagen
overproduction in experimental bleomycin lung fibrosis.
This highly interesting antibody was not yet humanized,
but this was in planning.
Anita Gilliam (Cleveland, OH, USA) studied a mouse
model of scleroderma-like graft versus host disease, Scl
GVHD, which is distinct from the more common lupus like
GVHD. The scleroderma-like features include skin and
lung fibrosis, increased synthesis of collagen, and TGFb1
mRNA. Interestingly, these models are based on produc-
ing chimeric animals in which bone marrow and spleen
cells from B10.D2 mice are transplanted into lethally irra-
diated BALB/c mice across minor histocompatibility loci,
leading to a sclerodermatous graft-versus-host disease.
The skin thickness in such animals is increased by 50%
and this can be monitored in vivo with ultrasound. The
animals do not produce autoantibodies, but skin infiltration
by Mac-1-positive macrophages occurs in later stages.
Increased production of TGFb occurs earlier according to
in situ hybridization analysis. It is not clear if lymphocytes
play any role, but large histiocytes and mast cells can be
seen and studied in digests from skin. These are CD11b
positive and are the predominating cell type by day 21.
They are probably chimeric cells. A polyclonal antibody
prepared in Dr Gilliam’s laboratory, when administered on
day 1 and day 6, was able to prevent both skin and lung
fibrosis and prevent skin infiltration with CD11b positive
cells. It was not clear whether established skin fibrosis
could be reversed.
David Glover (Cambridge, UK) reported on interesting
early human trials of two anti- TGFb2 human IgG4 anti-
bodies, called CAT 152 and CAT 192, selected by phage
antibody display technology. After promising results in
animals, CAT 152 was tried in glaucoma drainage surgery.
This study was stopped after the observation of an
unusual form of abnormal sheeting around retinal arteries
in three patients. Another study with this antibody in pre-
vention of fibrosis after glaucoma surgery was positive,
however, and superior to current routine therapy. The
other antibody, CAT 192, is in phase I study for safety.
The potential interest to use these or similar agents in
scleroderma patients is obvious.
Vasculopathy and its control
James Seibold (New Brunswick, NJ, USA) started didacti-
cally, by pointing out differences between fibrotic irre-
versible, inflammatory, and vascular abnormalities in
scleroderma. The latter consist of, for example, nephropa-
thy, pulmonary hypertension, sudden cardiac death, and
visceral and peripheral Raynaud’s. He also pointed out the
need for better biological markers.
Ariane Herrick (Manchester, UK) talked about oxidative
stress and attempts to control it. Free radicals cause lipid
peroxidation. The main actors are hydroxyl (HO•), superox-
ide (O•) produced during phagocytosis and reperfusion,
and nitric oxide (NO•) released from vascular endothelium.
Environmental toxins are a further source of oxidative
stress. Reduced thiol levels, increased 9,11-linoleic acid
levels, reduced ascorbic acid and selenium levels all
support the occurrence of oxidative stress in disease.
Low-density lipoprotein isolated from patients with sclero-
derma was more susceptible to oxidation in vitro. Although
much evidence is in support, therapeutic trials with super-
oxide dismutase (SOD) or with a combination of antioxi-
dant nutritional supplements combined with allopurinol
have failed to show any benefit.
Jill Belch (Dundee, UK) talked about therapy with NO•
donors. She pointed out that, although not mortal,
Raynaud’s contributes significantly to morbidity in sclero-
derma. Scleroderma patients show diminished vaso-
dilatation upon exposure to acetylcholine but normal
response to nitroprusside administered by iontophoresis.
However oral administration of the NO• donor,
L-arginine, had no significant effect on response to
acetylcholine or nitroprusside.
Lily Shen (Ann Arbor, MI, USA) addressed endothelin
antagonists. This is a large field of current development.
Animal studies showed that, in animals exposed to
hypoxia, ET-1 levels rise and pulmonary arterial pressure
goes up. An ET-1 antagonist inhibited this rise in pul-
monary arterial pressure. Although endothelin is a well-
documented vasoconstrictive factor in scleroderma, and a
number of inhibitors are available, no substantial practical
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Prostanoids and pulmonary hypertension
The use of stable prostaglandin I preparations in primary
pulmonary hypertension, pulmonary hypertension sec-
ondary to scleroderma and other circulatory disturbances
is a success story which started more than 10 years ago.
Glyn Belcher (London, UK) presented an overview without
too many new aspects. The problems of high cost and
intravenous administration limit the use of this therapy.
Studies are in progress with oral and inhalation prepara-
tions, which may in part overcome this problem.
Thomas Medsger (Pittsburgh, PA, USA) presented a ret-
rospective study based on more than 2500 patients
observed for more than 11 years on average, and which
was started by Dr Virginia Steen, now in Washington, DC,
USA. Comparing patients with pulmonary hypertension
and pulmonary fibrosis, the outstanding clinical difference
was the rapid progression of dyspnea after onset in the
former. Of the 182 cases identified, 80% were women,
and 145 had the limited form of scleroderma. The mean
disease duration when symptoms started was 13 years.
Risk factors were difficult to identify, although 97% had
Raynaud’s compared to 96% of controls. Past use of
calcium channel blocker was more common, as was
prevalence of skin ulceration, severe Raynaud’s, and
occurrence of new ulcers coinciding with onset of
dyspnea. Pulmonary function tests showed forced vital
capacity to be 78±18% compared to 67±20% in 393
patients with interstitial lung fibrosis and 87±20% in
patients without evidence of lung involvement. All figures
are expressed as percentage of the expected normal. The
corresponding figures for transfer factor for carbon
monoxide were 43%, 54% and 76%. Anticentromere anti-
bodies were found in 65% but anti-topoisomerase anti-
bodies in only 2% of the patients. The corresponding
figures for control patients were 34% and 37%. Eleven
patients had a history of scleroderma renal crisis on
average 4 years before onset of dyspnea. Of these only
one patient was still alive under continous Flolan therapy.
Four patients had undergone lung transplants; two sur-
vived. In order to be considered for transplantation
patients had to be nonsmokers, under the age of 65 and
without evidence of aspiration. Monitoring of pulmonary
pressure by Doppler echo under stress was probably
better than resting Doppler.
Lewis Rubin (La Jolla, CA, USA) talked about the patho-
genesis of pulmonary hypertension. He started by pointing
out the remarkable diversity of conditions that respond to
prostacyclin therapy. These include intrinsic vascular
disease, primary pulmonary hypertension, scleroderma-
and lupus-related pulmonary hypertension, Eisenmenger’s
syndrome, thromboembolic conditions etc. These do not
respond to calcium channel blocking agents. Thus it
seems unlikely that vasodilation is the mechanism of
action. Chronic effects include vasodilation, but also anti-
platelet and anti-proliferative effects. The histology of pul-
monary hypertension involves marked thickening of all
three layers of the vessel wall. The surprising fact is that
these changes are reversible. One can distinguish three
stages: a preclinical stage with rising pulmonary pressure;
a symptomatic stage with relatively stable pressure and
preserved cardiac output; and a progressive declining
stage with falling cardiac output. Left ventricular function
is decisive for survival. Potential mediators could be
increased levels of 5HT or thromboxane, increased
endothelin or reduced endothelin resistance. The ratio of
thromboxane to prostacyclin may be one important factor.
Increased endothelin expression is another factor in the
progressive stage. Closed K+ channels are also a patho-
genic factor. The most important acute effect of prostacy-
clin therapy is to improve cardiac output rather than to
reduce pulmonary pressure. Withdrawal of prostacyclin
may lead to life threatening rebound. In future work, it will
be important to study the mechanism of prostacyclin
effect, and also to try NO, endothelin receptor antago-
nists, selective phosphodiesterase inhibitors, K+ channel
openers, and perhaps gene therapy.
Fibroblasts, myofibroblasts and fibrocytes
Thomas Krieg (Cologne, Germany) summarized some of
the enigmatic facts regarding the fibroblast, of which he is
an eminent scholar. Our ignorance was attributed to two
factors. There is no reliable marker for fibroblasts, and
fibroblasts have not received enough research attention.
Fibroblasts are multifunctional and occur in different
shapes in inflammatory tissue, in the blood stream and in
bone marrow. As shown by his countryman Bayreuther,
normal fibroblasts develop from stem cells and occur in
three different forms: mitotic, postmitotic and degrading.
Seven different stages may be distinguished. The switch
from mitotic to postmitotic fibroblasts can arise sponta-
neously or be induced by treatment with mitomycin C. Col-
lagen synthesis is low in early fibroblasts and increases as
the cells change into later stages of development.
Mechanical tension, cytokine or integrin or other environ-
mental stimulation can effect activation of resting fibrob-
lasts, and can manifest itself transiently or permanently or
result in transformation into the myofibroblast form. Clonal
selection occurs in tissues as a result various stimuli,
which include cell to cell interactions, and may, as in the
case of scleroderma, result in excessive extracellular
matrix formation. All this information is important to keep in
mind when assessing the relevance of in vitro results with
cultured fibroblasts.
Richard Bucala (Manhasset, NY, USA) talked on his
favorite subject, the fibrocyte, a cell he has characterized
in peripheral blood. This has distinct surface markers, col-
lagen/CD13/CD34/CD45, and is probably a precursor
cell for tissue fibroblasts. Previous animal experiments had








































reported on an experimental wound model, where an
inserted sponge allowed fluid collection in order to study
the repair process. Within a day, spindle-shaped cells
invaded the sponge. Although these produced collagen and
were CD34-positive, and had MHC as well as adhesion
molecules expressed on the surface, they lacked monocyte
markers. Bucala reminded us that Metchnikov had pre-
dicted the existence of such cells. Fibrocytes were also
shown to carry chemokine receptors. They have been impli-
cated in infections such as borreliosis and schistosomiasis,
and clearly are important in wound healing. It is not defined
where in the cell hierarchy they belong, it is not unlikely that
they are precursors of the myofibroblasts. Engineered fibro-
cytes could become of interest as antitumor agents.
Three talks dealt with different regulating mechanisms of
fibroblast function. Livingston Van der Water (Boston, MA,
USA) described his work with fibronectin gene transcripts
resulting from alternative splicing events which occur
during development, tumor growth and tissue repair. This
results in fibronectin epitopes in the so-called EIIIA and
EIIIB regions, which transfer messages to fibroblasts.
Boris Hinz (Geneva, Switzerland) dealt with the myofibrob-
last, which is distinguished by its expression of alpha
smooth muscle actin, alphaSMA. This is brought about by
TGFb in concert with ED-A fibronectin, and functional
SMA is needed for wound contraction. Direct proof of this
was presented. Blocking of the N-terminal decapeptide of
alphaSMA had previously been shown to abolish collagen
contraction and polymerisation. The actual binding struc-
ture has now been identified as AcEEED (Acetyl-glutamic
acid–glutamic acid–glutamic acid–aspartic acid). Block-
ing of this structure in vivo abrogates wound contraction.
It is not known if myofibroblasts can be dedifferentiated.
Veli-Matti Kahari (Turku, Finland) studies the regulation of
collagenases and collagen synthesis. Matrix metallopro-
teinase (MMP)13 or collagenase III plays an important role
in repair, as shown in an experimental model of gingival
ulceration. MMP13 mRNA is induced by extracellular
signals including TNFa and TGFb. This is effected
through the extracellular signal-regulated kinase-1/2 and
the p38MAPK (mitogen-activated protein kinase) pathway.
This also leads to diminished collagen synthesis and
reminds us of the Bayreuther model mentioned above.
More on the vascular endothelium and
oxydative stress
Joseph Loscalzo (Boston, MA, USA) reported on progress
in our knowledge regarding the important functions of NO•
in regulating vascular tone and preventing thrombosis.
NO• inhibits thrombin receptor-activating peptide-induced
phosphoinositide 3-kinase activity in human platelets, and
this probably explains the de-aggregating effect of NO•.
Intracellular cGMP increase and calcium reduction are
involved in the reduced adhesion. A family with genetic
platelet unresponsiveness to NO• was studied, and two
children of 4 and 7 years old already showed signs of vas-
cular thrombosis. The roles of NO• and oxidative stress in
critical illness were the topics of a talk by Tim Evans
(London, UK). There is evidence from studies of bron-
choalveolar lavage fluid that neutrophils are implicated in
nitration and hydroxylation damage to proteins. Similar
mechanisms could operate in the anoxia in scleroderma.
Augustine Choi (New Haven, CT, USA) reported on heme
oxidases HO-1 and HO-2. These enzymes produce CO.
HO-1 is induced by oxidative stress and is a protective
mechanism; the protection is mediated by CO. CO, like
NO•, activates the enzyme guanylyl cyclase, leading to for-
mation of cGMP.
Cardiac and pulmonary fibrosis
Gerry Coghlan (London, UK) introduced the subject by
pointing out that asymptomatic fibrosis is not uncommon,
as shown in postmortem studies. Karl Weber (Memphis,
TN, USA) then gave an exciting expose of his work on the
fibrotic aspects of myocardial infarction. His main
message was that scar formation after a myocardial infarc-
tion is a dynamic process, and that fibrosis is not confined
to the site of initial damage but occurs in the entire cir-
cumference of the heart. He worked in an animal model
with coronary artery ligation. Interestingly this fibrosis
could be ameliorated by administration of ACE inhibitors
or angiotensin receptor 1 antagonists like Losartan. Ron
du Bois (London, UK) gave an overview of the distinct fea-
tures of scleroderma-related pulmonary fibrosis, and
pointed to the still not fully explored utility of high-resolu-
tion computer tomography, HRCT. The treatment indica-
tions were also discussed, and it was clear that early
treatment in asymptomatic stages is a field of debate. The
role of BAL findings is also controversial, although advo-
cates say that the quantity of neutrophils but not that of
eosinophils is helpful. It can be concluded that there is still
room for better diagnostic and prognostic information.
Barbara White (Baltimore, MD, USA) presented experi-
ence of treating fibrosing alveolitis with cyclophos-
phamide. Of 39 patients treated, 28 had a good outcome;
among 30 not treated, only 7 had a good outcome. These
figures can be compared with 34 patients with no evi-
dence of alveolitis, of whom 27 had a good outcome. My
conclusion is that this uncontrolled study, despite its limi-
tations, is another piece of evidence for the efficacy of
cyclophosphamide in this group of patients.
Therapeutic approaches to scleroderma
Dan Furst (Seattle, WA, USA), set the scene in this clini-
cal session by giving a clear overview of the state of the
art regarding clinical trials in scleroderma. The difficulties
often encountered include selecting valid end-points and
recruiting sufficient patients for reliable assessment. Novel
approaches to therapy included immunoablation with
autologous peripheral stem cell rescue, discussed by Alan
Tyndall (Basel, Switzerland); this approach is currentlyArthritis Research    Vol 3 No 1 Wollheim et al
being evaluated in the USA and Europe using similar and
well-controlled study protocols. Hermann Waldmann
(Oxford, UK) discussed the potential for using antibody
therapy directed against activated T cells, and in contrast
Marc Feldmann (London, UK) presented an overview of
the scientific background and trial results which form the
rational basis for remarkably successful use of TNFa neu-
tralizing treatments for rheumatoid arthritis. Overall, these
presentations left the impression that, once pivotal media-
tors or cell types for scleroderma are identified, then the
principles of targeted therapy are already validated. Trans-
lation of basic scientific observations into the clinical arena
is now feasible and this is reflected by the smooth integra-
tion of clinical and basic research topics at the workshop.
Licensing of new drugs for scleroderma
This lively session considered the particular difficulties
with obtaining licensing approval for novel therapies for
scleroderma. Despite many good trials and a number of
promising agents there are currently no approved disease-
modifying treatments for scleroderma. R Shah (London,
UK) presented a detailed account of the procedures
needed to license a drug through the Medicines Controls
Agency in the UK and James Seigal (Rockville, MD, USA)
gave an illuminating overview of Food and Drug Adminis-
tration (FDA) approaches, including some of the schemes
which are specifically targeted towards rare diseases such
as scleroderma.
Concluding comments
We hope it is evident from this account that scleroderma
research is moving forward in several ways. New thera-
peutic approaches are obviously arising from the
advances in molecular biology. An example is the recently
published study of recombinant human Relaxin [3], which,
however, did not show striking benefit and also showed an
unexplained lack of dose response. Mortality in sclero-
derma remains higher than in other connective tissue dis-
orders. This field needs the dedicated concerted actions
and communication facilitated by international workshops.
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